Delta 4
Main Menu
Main Menu
Delta4 Program

Long Covid / Anosmia

Aim

Identify novel compounds for treatment of patients with COVID-19.

Brief description

Anosmia is the partial or complete loss of the sense of smell. Anosmia can be temporary or permanent and may be caused by various factors, among others viral infection. Anosmia was also one of the main neurological symptoms of COVID-19, occurring in up to 55% of patients.

Funding agency: FFG (The Austrian Research Promotion Agency)
Status: Completed
Timeline: 2020 – 2022

Project Status

  • 1 Drug Identified
  • Patent Applications Filed

References

  • WO 2022/023533 A2: Antiviral use of liraglutide and gefitinib
  • WO 2024/017844 A1: Novel Use of Glucagon-Like Peptide 1 (Glp-1) Agonist

Partners

  • Medical University Vienna

Get Involved

Learn how you can contribute to the exciting work happening at Delta4

Careers

Forging the innovative treatments of the future requires brilliant minds and we’re always on the lookout for talent.
Explore Careers

Investors

Contact us to find out more about how you can invest with us and be a part of pioneering the next successful treatment.
Get In Touch

Medical Community

Learn how you can partner with us and combine our technology with your knowledge to develop treatments faster.
Partner With Us